ClinicalTrials.gov
public full text
Public Domain
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CMRA for US-guided-MWA of Liver Tumors#1102044
- Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment#1046992
- Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors#993232
- A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin#863721
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection#407739
Record · ID 1445264
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive